Welcome to Markets Desk, here's what's moving the needle today.
France is back in the crosshairs of sovereign debt markets, and the signal is unmistakable. Bond investors are now pricing in a non-trivial probability of a French default, according to Macquarie's global rates strategist Thierry Wizman. With both far-left and far-right political forces dominating the landscape, markets see no credible path to fiscal consolidation in the eurozone's second largest economy, and spreads are reflecting that verdict.
Turning to equities, Bristol Myers Squibb is trading at just nine point four times forward earnings, a valuation that looks cheap on the surface but carries a catch. The company is navigating active patent cliffs, with more expirations ahead, meaning near-term revenue pressure is real. Whether the multiple is a genuine value opportunity or a value trap depends heavily on how quickly the pipeline can offset those losses.
On the growth side, CrowdStrike remains a name worth watching for long-term investors. Recurring revenues are still expanding at a double-digit pace, which in a tighter spending environment for enterprise technology is genuinely notable. The cybersecurity sector broadly continues to benefit from structural demand, and CrowdStrike's platform model gives it meaningful pricing power over time.
That's the tape. Markets Desk, signing off the floor.
